BRIEF-Clovis Oncology presents data from phase 2 studies of rucaparib

* Nineteen patients (9%) discontinued treatment because of an adverse event.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.